Skip to main content
Top
Published in: BMC Infectious Diseases 1/2004

Open Access 01-12-2004 | Research article

Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae

Authors: Haa-Yung Lee, Ali Andalibi, Paul Webster, Sung-Kyun Moon, Karen Teufert, Sung-Ho Kang, Jian-Dong Li, Mitsuyoshi Nagura, Tomas Ganz, David J Lim

Published in: BMC Infectious Diseases | Issue 1/2004

Login to get access

Abstract

Background

Despite its direct connection to the nasopharynx which harbors otitis media pathogens as part of its normal flora, the middle ear cavity is kept free of these bacteria by as yet unknown mechanisms. Respiratory mucosal epithelia, including those of the middle ear and eustachian tube, secrete antimicrobial effectors including lysozyme, lactoferrin and β defensins-1 and -2. To elucidate the role of these innate immune molecules in the normal defense and maintenance of sterility of respiratory mucosa such as that of the middle ear, we assessed their effect on the respiratory pathogens nontypeable Haemophilus influenzae (NTHi) 12, Moraxella catarrhalis 035E, and Streptococcus pneumoniae 3, and 6B.

Methods

Two assay methods, the radial assay and the liquid broth assay, were employed for testing the antimicrobial activity of the molecules. This was done in order to minimize the possibility that the observed effects were artifacts of any single assay system employed. Also, transmission electron microscopy (TEM) was employed to evaluate the effect of antimicrobial innate immune molecules on OM pathogens. For the statistical analysis of the data, Student's t-test was performed.

Results

Results of the radial diffusion assay showed that β defensin-2 was active against all four OM pathogens tested, while treatment with β defensin-1 appeared to only affect M. catarrhalis. The radial assay results also showed that lysozyme was quite effective against S. pneumoniae 3 and 6B and was partially bacteriostatic/bactericidal against M. catarrhalis. Lysozyme however, appeared not to affect the growth of NTHi. Thus, lysozyme seems to have a more pronounced impact on the growth of the Gram-positive S. pneumoniae as compared to that of Gram-negative pathogens. Lactoferrin on the other hand, enhanced the growth of the bacteria tested. The results of the radial assays were confirmed using liquid broth assays for antimicrobial activity, and showed that lysozyme and β defensin-2 could act synergistically against S. pneumoniae 6B. Moreover, in the liquid broth assay, β defensin-1 showed a modest inhibitory effect on the growth of S. pneumoniae 6B. As assessed by ultrastructural analysis, lysozyme and β defensin-2, and to a much lesser extent, β defensin-1, appeared to be able to cause damage to the bacterial membranes.

Conclusions

Here we report that lysozyme and the β defensins can inhibit the growth of clinical isolates of otitis media pathogens – namely NTHi strain 12, S. pneumoniae strains 3 and 6B and M. catarrhalis strain 035E – and cause ultrastructural damage to these pathogens. Moreover, we demonstrate that lysozyme and β defensin-2 can act synergistically against S. pneumoniae. These findings are consistent with the concept that secreted antimicrobial peptides and other components of innate immunity constitute the first line of defense protecting host mucosal surfaces, including the tubotympanal (eustachian tube and middle ear cavity) mucosa, against pathogens.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bluestone C, Klein J: Otits media in infants and children. 1995, Philadelphia: W.B. Saunders Company, 2 Bluestone C, Klein J: Otits media in infants and children. 1995, Philadelphia: W.B. Saunders Company, 2
3.
go back to reference Shuto T, Imasato A, Jono H, Sakai A, Xu H, Watanabe T, Rixter DD, Kai H, Andalibi A, Linthicum F, et al: Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem. 2002, 277 (19): 17263-17270. 10.1074/jbc.M112190200.CrossRefPubMed Shuto T, Imasato A, Jono H, Sakai A, Xu H, Watanabe T, Rixter DD, Kai H, Andalibi A, Linthicum F, et al: Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem. 2002, 277 (19): 17263-17270. 10.1074/jbc.M112190200.CrossRefPubMed
4.
go back to reference Dagan R: Treatment of acute otitis media – challenges in the era of antibiotic resistance. Vaccine. 2000, 19 Suppl 1: S9-S16. 10.1016/S0264-410X(00)00272-3.CrossRefPubMed Dagan R: Treatment of acute otitis media – challenges in the era of antibiotic resistance. Vaccine. 2000, 19 Suppl 1: S9-S16. 10.1016/S0264-410X(00)00272-3.CrossRefPubMed
5.
go back to reference Rosenfeld R, Bluestone C: Evidence-Based Otitis Media. Saint Louis: BC Decker Inc. 1999 Rosenfeld R, Bluestone C: Evidence-Based Otitis Media. Saint Louis: BC Decker Inc. 1999
6.
go back to reference Bakaletz L: Otits Media. In: Polymicrobial Diseases. Edited by: Brogden K, Guthmiller J. 2002, Washington, D.C.: ASM Press Bakaletz L: Otits Media. In: Polymicrobial Diseases. Edited by: Brogden K, Guthmiller J. 2002, Washington, D.C.: ASM Press
7.
go back to reference Ichimiya I, Kawauchi H, Mogi G: Analysis of immunocompetent cells in the middle ear mucosa. Arch Otolaryngol Head Neck Surg. 1990, 116 (3): 324-330.CrossRefPubMed Ichimiya I, Kawauchi H, Mogi G: Analysis of immunocompetent cells in the middle ear mucosa. Arch Otolaryngol Head Neck Surg. 1990, 116 (3): 324-330.CrossRefPubMed
8.
go back to reference Prellner K, Kalm O, Pedersen FK: Pneumococcal antibodies and complement during and after periods of recurrent otitis. Int J Pediatr Otorhinolaryngol. 1984, 7 (1): 39-49.CrossRefPubMed Prellner K, Kalm O, Pedersen FK: Pneumococcal antibodies and complement during and after periods of recurrent otitis. Int J Pediatr Otorhinolaryngol. 1984, 7 (1): 39-49.CrossRefPubMed
9.
go back to reference Ryan AF: Immune-mediated otitis media in an animal model. Ann Otol Rhinol Laryngol Suppl. 1988, 132: 24-27.PubMed Ryan AF: Immune-mediated otitis media in an animal model. Ann Otol Rhinol Laryngol Suppl. 1988, 132: 24-27.PubMed
10.
go back to reference Teele DW, Klein JO, Rosner B: Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989, 160 (1): 83-94.CrossRefPubMed Teele DW, Klein JO, Rosner B: Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989, 160 (1): 83-94.CrossRefPubMed
11.
go back to reference Boe R, Silvola J, Yang J, Moens U, McCray PB, Stenfors LE, Seljfelid R: Human beta-defensin-1 mRNA is transcribed in tympanic membrane and adjacent auditory canal epithelium. Infect Immun. 1999, 67 (9): 4843-4846.PubMedPubMedCentral Boe R, Silvola J, Yang J, Moens U, McCray PB, Stenfors LE, Seljfelid R: Human beta-defensin-1 mRNA is transcribed in tympanic membrane and adjacent auditory canal epithelium. Infect Immun. 1999, 67 (9): 4843-4846.PubMedPubMedCentral
12.
go back to reference Lim DJ: Functional morphology of the mucosa of the middle ear and Eustachian tube. Ann Otol Rhinol Laryngol. 1976, 85 (2 Suppl 25 Pt 2): 36-43.PubMed Lim DJ: Functional morphology of the mucosa of the middle ear and Eustachian tube. Ann Otol Rhinol Laryngol. 1976, 85 (2 Suppl 25 Pt 2): 36-43.PubMed
13.
go back to reference Lim DJ, Chun YM, Lee HY, Moon SK, Chang KH, Li JD, Andalibi A: Cell biology of tubotympanum in relation to pathogenesis of otitis media – a review. Vaccine. 2000, 19 Suppl 1: S17-25. 10.1016/S0264-410X(00)00273-5.CrossRefPubMed Lim DJ, Chun YM, Lee HY, Moon SK, Chang KH, Li JD, Andalibi A: Cell biology of tubotympanum in relation to pathogenesis of otitis media – a review. Vaccine. 2000, 19 Suppl 1: S17-25. 10.1016/S0264-410X(00)00273-5.CrossRefPubMed
14.
go back to reference Nonomura N, Giebink GS, Zelterman D, Harada T, Juhn SK: Middle ear fluid lysozyme source in experimental pneumococcal otitis media. Ann Otol Rhinol Laryngol. 1991, 100 (7): 593-596.CrossRefPubMed Nonomura N, Giebink GS, Zelterman D, Harada T, Juhn SK: Middle ear fluid lysozyme source in experimental pneumococcal otitis media. Ann Otol Rhinol Laryngol. 1991, 100 (7): 593-596.CrossRefPubMed
15.
go back to reference Park K, Lim DJ: Development of secretory elements in murine tubotympanum: lysozyme and lactoferrin immunohistochemistry. Ann Otol Rhinol Laryngol. 1993, 102 (5): 385-395.CrossRefPubMed Park K, Lim DJ: Development of secretory elements in murine tubotympanum: lysozyme and lactoferrin immunohistochemistry. Ann Otol Rhinol Laryngol. 1993, 102 (5): 385-395.CrossRefPubMed
16.
go back to reference Suzuki T, Somekawa Y, Yamanaka N, Niida Y, Kataura A: Lactoferrin in middle ear effusion. Auris Nasus Larynx. 1985, 12 Suppl 1: S154-155.CrossRefPubMed Suzuki T, Somekawa Y, Yamanaka N, Niida Y, Kataura A: Lactoferrin in middle ear effusion. Auris Nasus Larynx. 1985, 12 Suppl 1: S154-155.CrossRefPubMed
17.
go back to reference Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, Li JD: Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem. 2002, 277 (49): 47444-47450. 10.1074/jbc.M208140200.CrossRefPubMed Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, Li JD: Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem. 2002, 277 (49): 47444-47450. 10.1074/jbc.M208140200.CrossRefPubMed
18.
go back to reference Hanamure Y, Lim DJ: Normal distribution of lysozyme- and lactoferrin-secreting cells in the chinchilla tubotympanum. Am J Otolaryngol. 1986, 7 (6): 410-425.CrossRefPubMed Hanamure Y, Lim DJ: Normal distribution of lysozyme- and lactoferrin-secreting cells in the chinchilla tubotympanum. Am J Otolaryngol. 1986, 7 (6): 410-425.CrossRefPubMed
19.
go back to reference Lim DJ, Liu YS, Birck H: Secretory lysozyme of the human middle ear mucosa: immunocytochemical localization. Ann Otol Rhinol Laryngol. 1976, 85 (1 Pt 1): 50-60.CrossRefPubMed Lim DJ, Liu YS, Birck H: Secretory lysozyme of the human middle ear mucosa: immunocytochemical localization. Ann Otol Rhinol Laryngol. 1976, 85 (1 Pt 1): 50-60.CrossRefPubMed
20.
go back to reference Liu YS, Lim DJ, Lang RW, Birck HG: Chronic middle ear effusions. Immunochemical and bacteriological investigations. Arch Otolaryngol. 1975, 101 (5): 278-286.CrossRefPubMed Liu YS, Lim DJ, Lang RW, Birck HG: Chronic middle ear effusions. Immunochemical and bacteriological investigations. Arch Otolaryngol. 1975, 101 (5): 278-286.CrossRefPubMed
21.
go back to reference Stenfors LE: Non-specific and specific immunity to bacterial invasion of the middle ear cavity. Int J Pediatr Otorhinolaryngol. 1999, 49 Suppl 1: S223-226. 10.1016/S0165-5876(99)00164-0.CrossRefPubMed Stenfors LE: Non-specific and specific immunity to bacterial invasion of the middle ear cavity. Int J Pediatr Otorhinolaryngol. 1999, 49 Suppl 1: S223-226. 10.1016/S0165-5876(99)00164-0.CrossRefPubMed
22.
go back to reference Chung MH, Choi JY, Lee WS, Kim HN, Yoon JH: Compositional difference in middle ear effusion: mucous versus serous. Laryngoscope. 2002, 112 (1): 152-155.CrossRefPubMed Chung MH, Choi JY, Lee WS, Kim HN, Yoon JH: Compositional difference in middle ear effusion: mucous versus serous. Laryngoscope. 2002, 112 (1): 152-155.CrossRefPubMed
23.
go back to reference Harada T, Juhn SK, Adams GL: Lysozyme levels in middle ear effusion and serum in otitis media. Arch Otolaryngol Head Neck Surg. 1990, 116 (1): 54-56.CrossRefPubMed Harada T, Juhn SK, Adams GL: Lysozyme levels in middle ear effusion and serum in otitis media. Arch Otolaryngol Head Neck Surg. 1990, 116 (1): 54-56.CrossRefPubMed
24.
go back to reference Moon SK, Lee HY, Li JD, Nagura M, Kang SH, Chun YM, Linthicum FH, Ganz T, Andalibi A, Lim DJ: Activation of a Src-dependent Raf-MEKl/2-ERK signaling pathway is required for IL-1 alpha-induced upregulation of beta-defensin 2 in human middle ear epithelial cells. Biochim Biophys Acta. 2002, 1590 (1–3): 41-51.CrossRefPubMed Moon SK, Lee HY, Li JD, Nagura M, Kang SH, Chun YM, Linthicum FH, Ganz T, Andalibi A, Lim DJ: Activation of a Src-dependent Raf-MEKl/2-ERK signaling pathway is required for IL-1 alpha-induced upregulation of beta-defensin 2 in human middle ear epithelial cells. Biochim Biophys Acta. 2002, 1590 (1–3): 41-51.CrossRefPubMed
25.
go back to reference Watt SA, Kular G, Fleming IN, Downes CP, Lucocq JM: Subcellular localization of phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology domain of phospholipase C deltal. Biochem J. 2002, 363 (Pt 3): 657-666. 10.1042/0264-6021:3630657.CrossRefPubMedPubMedCentral Watt SA, Kular G, Fleming IN, Downes CP, Lucocq JM: Subcellular localization of phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology domain of phospholipase C deltal. Biochem J. 2002, 363 (Pt 3): 657-666. 10.1042/0264-6021:3630657.CrossRefPubMedPubMedCentral
26.
go back to reference Lim DJ, DeMaria TF: Immunobarriers of the tubotympanum. Acta Otolaryngol. 1987, 103 (5–6): 355-362.PubMed Lim DJ, DeMaria TF: Immunobarriers of the tubotympanum. Acta Otolaryngol. 1987, 103 (5–6): 355-362.PubMed
27.
go back to reference Mogi G, Maeda S, Watanabe N: The development of mucosal immunity in guinea pig middle ears. Int J Pediatr Otorhinolaryngol. 1980, 1 (4): 331-349. 10.1016/0165-5876(80)90007-5.CrossRefPubMed Mogi G, Maeda S, Watanabe N: The development of mucosal immunity in guinea pig middle ears. Int J Pediatr Otorhinolaryngol. 1980, 1 (4): 331-349. 10.1016/0165-5876(80)90007-5.CrossRefPubMed
28.
go back to reference Hu WG, Chen J, Battey JF, Gu XX: Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins. Infect Immun. 2000, 68 (9): 4980-4985. 10.1128/IAI.68.9.4980-4985.2000.CrossRefPubMedPubMedCentral Hu WG, Chen J, Battey JF, Gu XX: Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins. Infect Immun. 2000, 68 (9): 4980-4985. 10.1128/IAI.68.9.4980-4985.2000.CrossRefPubMedPubMedCentral
29.
go back to reference Hausdorff WP, Yothers G, Dagan R, Kilpi T, Pelton SI, Cohen R, Jacobs MR, Kaplan SL, Levy C, Lopez EL, et al: Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J. 2002, 21 (11): 1008-1016. 10.1097/00006454-200211000-00007.CrossRefPubMed Hausdorff WP, Yothers G, Dagan R, Kilpi T, Pelton SI, Cohen R, Jacobs MR, Kaplan SL, Levy C, Lopez EL, et al: Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J. 2002, 21 (11): 1008-1016. 10.1097/00006454-200211000-00007.CrossRefPubMed
30.
go back to reference Harder J, Bartels J, Christophers E, Schroder JM: A peptide antibiotic from human skin. Nature. 1997, 387 (6636): 861-10.1038/43088.CrossRefPubMed Harder J, Bartels J, Christophers E, Schroder JM: A peptide antibiotic from human skin. Nature. 1997, 387 (6636): 861-10.1038/43088.CrossRefPubMed
31.
go back to reference Hiratsuka T, Nakazato M, Date Y, Ashitani J, Minematsu T, Chino N, Matsukura S: Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. Biochem Biophys Res Commun. 1998, 249 (3): 943-947. 10.1006/bbrc.1998.9239.CrossRefPubMed Hiratsuka T, Nakazato M, Date Y, Ashitani J, Minematsu T, Chino N, Matsukura S: Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. Biochem Biophys Res Commun. 1998, 249 (3): 943-947. 10.1006/bbrc.1998.9239.CrossRefPubMed
32.
go back to reference Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, Ganz T: Human beta- defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol. 2002, 118 (2): 275-281. 10.1046/j.0022-202x.2001.01651.x.CrossRefPubMed Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, Ganz T: Human beta- defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol. 2002, 118 (2): 275-281. 10.1046/j.0022-202x.2001.01651.x.CrossRefPubMed
33.
go back to reference Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, Tack BF, McCray PB: Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun. 1999, 67 (6): 2740-2745.PubMedPubMedCentral Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, Tack BF, McCray PB: Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun. 1999, 67 (6): 2740-2745.PubMedPubMedCentral
34.
go back to reference Lehrer RI, Ganz T: Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol. 1999, 11 (1): 23-27. 10.1016/S0952-7915(99)80005-3.CrossRefPubMed Lehrer RI, Ganz T: Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol. 1999, 11 (1): 23-27. 10.1016/S0952-7915(99)80005-3.CrossRefPubMed
35.
go back to reference McNamara N, Van R, Tuchin OS, Fleiszig SM: Ocular surface epithelia express mRNA for human beta defensin-2. Exp Eye Res. 1999, 69 (5): 483-490. 10.1006/exer.1999.0722.CrossRefPubMed McNamara N, Van R, Tuchin OS, Fleiszig SM: Ocular surface epithelia express mRNA for human beta defensin-2. Exp Eye Res. 1999, 69 (5): 483-490. 10.1006/exer.1999.0722.CrossRefPubMed
36.
go back to reference Ganz T, Lehrer RI: Antimicrobial peptides of vertebrates. Curr Opin Immunol. 1998, 10 (1): 41-44. 10.1016/S0952-7915(98)80029-0.CrossRefPubMed Ganz T, Lehrer RI: Antimicrobial peptides of vertebrates. Curr Opin Immunol. 1998, 10 (1): 41-44. 10.1016/S0952-7915(98)80029-0.CrossRefPubMed
37.
go back to reference Schroder JM, Harder J: Human beta-defensin-2. Int J Biochem Cell Biol. 1999, 31 (6): 645-651. 10.1016/S1357-2725(99)00013-8.CrossRefPubMed Schroder JM, Harder J: Human beta-defensin-2. Int J Biochem Cell Biol. 1999, 31 (6): 645-651. 10.1016/S1357-2725(99)00013-8.CrossRefPubMed
38.
go back to reference Starner TD, Swords WE, Apicella MA, McCray PB: Susceptibility of nontypeable Haemophilus influenzae to human beta-defensins is influenced by lipooligosaccharide acylation. Infect Immun. 2002, 70 (9): 5287-5289. 10.1128/IAI.70.9.5287-5289.2002.CrossRefPubMedPubMedCentral Starner TD, Swords WE, Apicella MA, McCray PB: Susceptibility of nontypeable Haemophilus influenzae to human beta-defensins is influenced by lipooligosaccharide acylation. Infect Immun. 2002, 70 (9): 5287-5289. 10.1128/IAI.70.9.5287-5289.2002.CrossRefPubMedPubMedCentral
39.
go back to reference Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P: Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods. 1991, 137 (2): 167-173. 10.1016/0022-1759(91)90021-7.CrossRefPubMed Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P: Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods. 1991, 137 (2): 167-173. 10.1016/0022-1759(91)90021-7.CrossRefPubMed
40.
go back to reference O'Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T, Kagnoff MF: Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol. 1999, 163 (12): 6718-6724.PubMed O'Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T, Kagnoff MF: Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol. 1999, 163 (12): 6718-6724.PubMed
41.
go back to reference Schnapp D, Reid CJ, Harris A: Localization of expression of human beta defensin-1 in the pancreas and kidney. J Pathol. 1998, 186 (1): 99-103. 10.1002/(SICI)1096-9896(199809)186:1<99::AID-PATH133>3.0.CO;2-#.CrossRefPubMed Schnapp D, Reid CJ, Harris A: Localization of expression of human beta defensin-1 in the pancreas and kidney. J Pathol. 1998, 186 (1): 99-103. 10.1002/(SICI)1096-9896(199809)186:1<99::AID-PATH133>3.0.CO;2-#.CrossRefPubMed
42.
go back to reference Bals R, Goldman MJ, Wilson JM: Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun. 1998, 66 (3): 1225-1232.PubMedPubMedCentral Bals R, Goldman MJ, Wilson JM: Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun. 1998, 66 (3): 1225-1232.PubMedPubMedCentral
43.
go back to reference Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, et al: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA. 1998, 95 (25): 14961-14966. 10.1073/pnas.95.25.14961.CrossRefPubMedPubMedCentral Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, et al: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA. 1998, 95 (25): 14961-14966. 10.1073/pnas.95.25.14961.CrossRefPubMedPubMedCentral
44.
go back to reference Dohrman A, Tsuda T, Escudier E, Cardone M, Jany B, Gum J, Kim Y, Basbaum C: Distribution of lysozyme and mucin (MUC2 and MUC3) mRNA in human bronchus. Exp Lung Res. 1994, 20 (4): 367-380.CrossRefPubMed Dohrman A, Tsuda T, Escudier E, Cardone M, Jany B, Gum J, Kim Y, Basbaum C: Distribution of lysozyme and mucin (MUC2 and MUC3) mRNA in human bronchus. Exp Lung Res. 1994, 20 (4): 367-380.CrossRefPubMed
45.
go back to reference Klockars M, Osserman EF: Localization of lysozyme in normal rat tissues by an immunoperoxidase method. J Histochem Cytochem. 1974, 22 (3): 139-146.CrossRefPubMed Klockars M, Osserman EF: Localization of lysozyme in normal rat tissues by an immunoperoxidase method. J Histochem Cytochem. 1974, 22 (3): 139-146.CrossRefPubMed
46.
go back to reference Klockars M, Reitamo S: Tissue distribution of lysozyme in man. J Histochem Cytochem. 1975, 23 (12): 932-940.CrossRefPubMed Klockars M, Reitamo S: Tissue distribution of lysozyme in man. J Histochem Cytochem. 1975, 23 (12): 932-940.CrossRefPubMed
47.
go back to reference Montagne P, Cuilliere ML, Mole C, Bene MC, Faure G: Changes in lactoferrin and lysozyme levels in human milk during the first twelve weeks of lactation. Adv Exp Med Biol. 2001, 501: 241-247.CrossRefPubMed Montagne P, Cuilliere ML, Mole C, Bene MC, Faure G: Changes in lactoferrin and lysozyme levels in human milk during the first twelve weeks of lactation. Adv Exp Med Biol. 2001, 501: 241-247.CrossRefPubMed
48.
go back to reference Chun W, Hancock RE: Action of lysozyme and nisin mixtures against lactic acid bacteria. Int J Food Microbiol. 2000, 60 (1): 25-32. 10.1016/S0168-1605(00)00330-5.CrossRefPubMed Chun W, Hancock RE: Action of lysozyme and nisin mixtures against lactic acid bacteria. Int J Food Microbiol. 2000, 60 (1): 25-32. 10.1016/S0168-1605(00)00330-5.CrossRefPubMed
49.
go back to reference Aebi C, Stone B, Beucher M, Cope LD, Maciver I, Thomas SE, McCracken GH, Sparling PF, Hansen EJ: Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin. Infect Immun. 1996, 64 (6): 2024-2030.PubMedPubMedCentral Aebi C, Stone B, Beucher M, Cope LD, Maciver I, Thomas SE, McCracken GH, Sparling PF, Hansen EJ: Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin. Infect Immun. 1996, 64 (6): 2024-2030.PubMedPubMedCentral
50.
go back to reference Bonnah RA, Yu RH, Wong H, Schryvers AB: Biochemical and immunological properties of lactoferrin binding proteins from Moraxella (Branhamella) catarrhalis. Microb Pathog. 1998, 24 (2): 89-100. 10.1006/mpat.1997.0173.CrossRefPubMed Bonnah RA, Yu RH, Wong H, Schryvers AB: Biochemical and immunological properties of lactoferrin binding proteins from Moraxella (Branhamella) catarrhalis. Microb Pathog. 1998, 24 (2): 89-100. 10.1006/mpat.1997.0173.CrossRefPubMed
51.
go back to reference Ellison RT: The effects of lactoferrin on gram-negative bacteria. Adv Exp Med Biol. 1994, 357: 71-90.CrossRefPubMed Ellison RT: The effects of lactoferrin on gram-negative bacteria. Adv Exp Med Biol. 1994, 357: 71-90.CrossRefPubMed
52.
go back to reference Qiu J, Hendrixson DR, Baker EN, Murphy TF, St Geme JW, Plaut AG: Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci USA. 1998, 95 (21): 12641-12646. 10.1073/pnas.95.21.12641.CrossRefPubMedPubMedCentral Qiu J, Hendrixson DR, Baker EN, Murphy TF, St Geme JW, Plaut AG: Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci USA. 1998, 95 (21): 12641-12646. 10.1073/pnas.95.21.12641.CrossRefPubMedPubMedCentral
53.
go back to reference Hanson LA, Korotkova M, Haversen L, Mattsby-Baltzer I, Hahn-Zoric M, Silfverdal SA, Strandvik B, Telemo E: Breast-feeding, a complex support system for the offspring. Pediatr Int. 2002, 44 (4): 347-352. 10.1046/j.1442-200X.2002.t01-1-01592.x.CrossRefPubMed Hanson LA, Korotkova M, Haversen L, Mattsby-Baltzer I, Hahn-Zoric M, Silfverdal SA, Strandvik B, Telemo E: Breast-feeding, a complex support system for the offspring. Pediatr Int. 2002, 44 (4): 347-352. 10.1046/j.1442-200X.2002.t01-1-01592.x.CrossRefPubMed
54.
go back to reference Plaut AG, Qiu J, St Geme JW: Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. Vaccine. 2000, 19 Suppl 1: S148-152. 10.1016/S0264-410X(00)00296-6.CrossRefPubMed Plaut AG, Qiu J, St Geme JW: Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. Vaccine. 2000, 19 Suppl 1: S148-152. 10.1016/S0264-410X(00)00296-6.CrossRefPubMed
55.
go back to reference Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, Kim KS, McCormack FX: Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest. 2003, 111 (10): 1589-1602. 10.1172/JCI200316889.CrossRefPubMedPubMedCentral Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, Kim KS, McCormack FX: Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest. 2003, 111 (10): 1589-1602. 10.1172/JCI200316889.CrossRefPubMedPubMedCentral
56.
go back to reference Shimoda M, Ohki K, Shimamoto Y, Kohashi O: Morphology of defensin-treated Staphylococcus aureus. Infect Immun. 1995, 63 (8): 2886-2891.PubMedPubMedCentral Shimoda M, Ohki K, Shimamoto Y, Kohashi O: Morphology of defensin-treated Staphylococcus aureus. Infect Immun. 1995, 63 (8): 2886-2891.PubMedPubMedCentral
57.
go back to reference Singh PK, Tack BF, McCray PB, Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol. 2000, 279 (5): L799-805.PubMed Singh PK, Tack BF, McCray PB, Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol. 2000, 279 (5): L799-805.PubMed
Metadata
Title
Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae
Authors
Haa-Yung Lee
Ali Andalibi
Paul Webster
Sung-Kyun Moon
Karen Teufert
Sung-Ho Kang
Jian-Dong Li
Mitsuyoshi Nagura
Tomas Ganz
David J Lim
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2004
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-4-12

Other articles of this Issue 1/2004

BMC Infectious Diseases 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.